机构:[1]IRCCS Osped San Raffaele, Milan, Italy;[2]Ctr Onkol, Warsaw, Poland;[3]Samsung Med Ctr, Seoul, South Korea;[4]IRCCS Fdn Ist Nazl Tumori, Milan, Italy;[5]Natl Yang Ming Univ, Taipei Vet Gen Hosp, Taipei, Taiwan;[6]Koo Fdn Sun Yat Sen Canc Ctr, Taipei, Taiwan;中山大学肿瘤防治中心[7]Hosp Clin Univ, INCLIVA Biomed Res Inst, Valencia, Spain;[8]Hosp Reina Sofia, Cordoba, Spain;[9]NN Petrov Res Inst Oncol, St Petersburg, Russia;[10]Seoul Natl Univ Hosp Canc Res Inst, Seoul, South Korea;[11]CHU Quebec, Hop St Sacrement, Quebec City, PQ, Canada;[12]Hosp Ernesto Dornelles, Porto Alegre, RS, Brazil;[13]Fdn Michelangelo, Milan, Italy
第一作者机构:[1]IRCCS Osped San Raffaele, Milan, Italy;[2]Ctr Onkol, Warsaw, Poland;[3]Samsung Med Ctr, Seoul, South Korea;[4]IRCCS Fdn Ist Nazl Tumori, Milan, Italy;[5]Natl Yang Ming Univ, Taipei Vet Gen Hosp, Taipei, Taiwan;[6]Koo Fdn Sun Yat Sen Canc Ctr, Taipei, Taiwan;[7]Hosp Clin Univ, INCLIVA Biomed Res Inst, Valencia, Spain;[8]Hosp Reina Sofia, Cordoba, Spain;[9]NN Petrov Res Inst Oncol, St Petersburg, Russia;[10]Seoul Natl Univ Hosp Canc Res Inst, Seoul, South Korea;[11]CHU Quebec, Hop St Sacrement, Quebec City, PQ, Canada;[12]Hosp Ernesto Dornelles, Porto Alegre, RS, Brazil;[13]Fdn Michelangelo, Milan, Italy
推荐引用方式(GB/T 7714):
Bianchini G.,Pienkowski T.,Im Y-H,et al.Proliferation and p21 refine risk of relapse in residual disease after HER2-directed therapies[J].CANCER RESEARCH.2017,77:-.doi:10.1158/1538-7445.SABCS16-P1-09-04.
APA:
Bianchini, G.,Pienkowski, T.,Im, Y-H,Bianchi, G. V.,Tseng, L-M...&Gianni, L..(2017).Proliferation and p21 refine risk of relapse in residual disease after HER2-directed therapies.CANCER RESEARCH,77,
MLA:
Bianchini, G.,et al."Proliferation and p21 refine risk of relapse in residual disease after HER2-directed therapies".CANCER RESEARCH 77.(2017):-